Page last updated: 2024-10-20
uracil and Nausea
uracil has been researched along with Nausea in 50 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 9.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "Although combination chemotherapy with trifluridine/tipiracil (TAS-102) and bevacizumab (BEV) is highly effective for metastatic unresectable colorectal cancer (mCRC), this combination chemotherapy often induces nausea and vomiting." | 8.31 | Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy. ( Fujii, H; Hirose, C; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Sadaka, S; Suzuki, A; Takahashi, T; Watanabe, D, 2023) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 7.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 6.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "The purpose of this study was to evaluate the efficacy, assessed as response rate, and toxicity of UFT (Tegafur-Uracil) in combination with oxaliplatin as first-line treatment of advanced colorectal cancer (CRC)." | 5.11 | Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. ( Antón-Aparicio, L; Aparicio, J; Constela, M; Dorta, FJ; Feliu, J; Fonseca, E; García-Girón, C; Gonzalez-Baron, M; Lomas, M; Vicent, JM, 2004) |
| "The combination of epirubicin, cisplatin and UFT showed anticancer activity against metastatic gastric adenocarcinoma, had a tolerable toxicity profile and showed excellent patient compliance." | 5.11 | A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. ( Byun, JH; Choi, MG; Chung, IS; Hong, YS; Kang, JH; Kim, KW; Lee, KS; Lee, MA; Moon, DH; Park, SY; Shim, BY; Woo, IS, 2005) |
| "Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin." | 5.08 | A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. ( Kim, BS; Kim, JG; Kim, JS; Kim, YH; Park, YT; Shin, SW, 1997) |
| "A double blind study to compare the efficacy of oral UFT (400 mg Tegafur (FT) plus 896 mg uracil/day) with that of oral FT (800 mg/day) on advanced breast cancer was performed between November, 1986, and November, 1989." | 5.07 | A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. ( Nomura, Y; Ohsaki, A; Tashiro, H, 1994) |
| "Although combination chemotherapy with trifluridine/tipiracil (TAS-102) and bevacizumab (BEV) is highly effective for metastatic unresectable colorectal cancer (mCRC), this combination chemotherapy often induces nausea and vomiting." | 4.31 | Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy. ( Fujii, H; Hirose, C; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Sadaka, S; Suzuki, A; Takahashi, T; Watanabe, D, 2023) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "To evaluate ambulatory patient cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 19 patients with non-curative or recurrent colorectal cancer who were treated by Uracil/Tegafur (UFT) plus oral Leucovorin (UZEL) for the past 2 years." | 3.73 | [Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer]. ( Fujiwara, H; Hamabe, Y; Ishida, T; Kaji, M; Mukai, H; Mukubou, H; Onishi, N; Sato, S; Toyokawa, A; Tsujimura, T; Tsukamoto, T; Wakahara, T; Wakita, K; Watanabe, A, 2005) |
| "Concomitant treatment with 5-fluorouracil (5-FU) and Leucovorin (LV) is positioned as the standard chemotherapy against colorectal cancer." | 3.72 | [Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer]. ( Anazawa, S; Hirai, K; Kawahara, H; Ogawa, M; Sakuyama, T; Sato, K; Takao, Y; Yamazaki, Y; Yokoyama, M, 2004) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 3.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| " Maximum concentrations of both drugs decreased by approximately 40%, indicating that food influenced the absorption and bioavailability of trifluridine and tipiracil hydrochloride, respectively." | 2.82 | Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. ( Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 2.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)." | 2.72 | Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. ( Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006) |
| ") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers." | 2.71 | Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. ( Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005) |
| "Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies." | 2.71 | A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Okusaka, T; Ueno, H, 2005) |
| " The most appropriate dosing option appeared to be 400 mg x m(-2) per day of oral UFT for 14 consecutive days with 900 mg x m(-2) gemcitabine on days 8 and 15." | 2.70 | A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer. ( Asoh, H; Ichinose, Y; Semba, H; Seto, T; Yamamoto, H; Yoh, K, 2002) |
| "Gastric cancer is the most chemosensitive adenocarcinoma among digestive neoplasms." | 2.68 | The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group. ( Belón, J; de Castro, J; Espinosa, E; Feliu, J; García Alfonso, P; García Girón, C; Garrido, P; González Barón, M; Lomas, M; Ordóñez, A; Zamora, P, 1997) |
| " Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day." | 2.68 | Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996) |
| "Thirty-four patients with advanced gastric cancer were treated with combination chemotherapy employing Tegafur-Uracil (UFT), etoposide, Adriamycin, and Cisplatinum (CDDP) (UFT-EAP therapy)." | 2.67 | Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer. ( Chin, K; Hattori, T; Hayakawa, M; Maeda, H; Morise, K; Morooka, Y; Saito, H; Sugihara, M, 1994) |
| "Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial." | 2.46 | Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma. ( Gao, XS; Li, XY; Liu, CX, 2010) |
| " Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95." | 1.43 | Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. ( Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016) |
| "We report a rare patient with a DPD deficiency." | 1.33 | [A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency]. ( Arai, K; Hashimoto, T; Hiruma, K; Iwasaki, Y; Matsumoto, H; Saze, Z; Takahashi, K; Yamaguchi, T; Yamashita, Y; Yasutome, M, 2006) |
| "Tegafur is a prodrug that is converted to 5-fluorouracil (5-FU) and has been reported to be less toxic and to have a higher therapeutic index." | 1.31 | Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Hsu, TC; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, HS; Wang, WS; Yang, SH; Yen, CC, 2000) |
| "Despite this preventative treatment, nausea and/or vomiting occurred in over one-third of all the courses." | 1.28 | [Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin]. ( Aoki, Y; Horiuchi, Y; Kamikawa, R; Kyokane, K; Miwa, Y; Nagai, H; Ninomiya, E; Noro, T; Suga, S; Yasue, K, 1990) |
| " Pharmacokinetic study after single oral administration of 300 to 1200 mg of UFT-E was carried out in cancer patients measuring tagafur, uracil and 5-FU levels in serum, normal tissue and tumor tissue using HPLC and GC-mass." | 1.27 | [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients]. ( Fujii, S; Hoshino, A; Kamiya, O; Kimura, K; Kojima, T; Nagata, K; Ohara, K; Sugihara, T; Suzuki, M; Yamada, M, 1983) |
| " Total Ftorafur (FT) results using the same criteria from the UFT phase II study revealed, from a comparison of dosage and disease type, that UFT did not enhance FT side effects; rather, it markedly increases effectiveness." | 1.27 | [Report on nationwide pooled data and cohort investigation in UFT phase II study]. ( Kimura, K; Ota, K; Taguchi, T, 1987) |
Research
Studies (50)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (14.00) | 18.7374 |
| 1990's | 20 (40.00) | 18.2507 |
| 2000's | 16 (32.00) | 29.6817 |
| 2010's | 6 (12.00) | 24.3611 |
| 2020's | 1 (2.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Matsuoka, S | 2 |
| Fujii, H | 1 |
| Iihara, H | 1 |
| Ohata, K | 1 |
| Hirose, C | 1 |
| Watanabe, D | 1 |
| Sadaka, S | 1 |
| Kiyama, S | 1 |
| Makiyama, A | 1 |
| Takahashi, T | 1 |
| Kobayashi, R | 1 |
| Matsuhashi, N | 1 |
| Suzuki, A | 1 |
| Harrison, SA | 1 |
| Bashir, MR | 1 |
| Guy, CD | 1 |
| Zhou, R | 1 |
| Moylan, CA | 1 |
| Frias, JP | 1 |
| Alkhouri, N | 1 |
| Bansal, MB | 1 |
| Baum, S | 1 |
| Neuschwander-Tetri, BA | 1 |
| Taub, R | 1 |
| Moussa, SE | 1 |
| Kimura, M | 2 |
| Usami, E | 2 |
| Teramachi, H | 2 |
| Yoshimura, T | 2 |
| Hayakawa, N | 1 |
| Matsumoto, K | 1 |
| Sato, A | 2 |
| Sakamoto, H | 1 |
| Ezaki, T | 1 |
| Maeda, T | 1 |
| Ninomiya, A | 1 |
| Nakamura, S | 1 |
| Yoshino, T | 1 |
| Kojima, T | 2 |
| Bando, H | 1 |
| Yamazaki, T | 1 |
| Naito, Y | 1 |
| Mukai, H | 2 |
| Fuse, N | 1 |
| Goto, K | 1 |
| Ito, Y | 1 |
| Doi, T | 1 |
| Ohtsu, A | 1 |
| Go, M | 1 |
| Iwai, M | 1 |
| Ito, D | 1 |
| Asano, H | 1 |
| Liu, CX | 1 |
| Li, XY | 1 |
| Gao, XS | 1 |
| Fujimori, S | 1 |
| Kurita, H | 1 |
| Azegami, T | 1 |
| Koike, T | 1 |
| Ohtsuka, A | 1 |
| Kobayashi, H | 1 |
| Tanaka, K | 1 |
| Kurashina, K | 1 |
| VIETTI, TJ | 1 |
| BERRY, DH | 1 |
| FERNBACH, DJ | 1 |
| LUSHER, J | 1 |
| SUTOW, WW | 1 |
| Sakuyama, T | 1 |
| Yokoyama, M | 2 |
| Ogawa, M | 2 |
| Takao, Y | 1 |
| Sato, K | 1 |
| Kawahara, H | 1 |
| Anazawa, S | 1 |
| Yamazaki, Y | 1 |
| Hirai, K | 1 |
| Feliu, J | 3 |
| Vicent, JM | 1 |
| García-Girón, C | 1 |
| Constela, M | 1 |
| Fonseca, E | 1 |
| Aparicio, J | 1 |
| Lomas, M | 2 |
| Antón-Aparicio, L | 1 |
| Dorta, FJ | 1 |
| Gonzalez-Baron, M | 1 |
| Woo, IS | 1 |
| Moon, DH | 1 |
| Shim, BY | 1 |
| Lee, MA | 1 |
| Byun, JH | 1 |
| Kim, KW | 1 |
| Kang, JH | 1 |
| Choi, MG | 1 |
| Chung, IS | 1 |
| Hong, YS | 1 |
| Park, SY | 1 |
| Lee, KS | 1 |
| Nio, Y | 1 |
| Hashimoto, K | 1 |
| Yano, S | 1 |
| Itakura, M | 1 |
| Koike, M | 1 |
| Yamaguchi, K | 1 |
| Endo, S | 1 |
| Tsuji, M | 1 |
| Higami, T | 1 |
| Maruyama, R | 1 |
| Ikeda, M | 2 |
| Okusaka, T | 2 |
| Ueno, H | 2 |
| Morizane, C | 2 |
| Furuse, J | 2 |
| Ishii, H | 2 |
| Ito, T | 1 |
| Hata, Y | 1 |
| Nakajima, N | 1 |
| Yokoyama, R | 1 |
| Honda, S | 1 |
| Sano, F | 1 |
| Akasaka, Y | 1 |
| Ohmori, K | 1 |
| Toyokawa, A | 1 |
| Tsujimura, T | 1 |
| Hamabe, Y | 1 |
| Sato, S | 1 |
| Mukubou, H | 1 |
| Wakahara, T | 1 |
| Kaji, M | 1 |
| Tsukamoto, T | 1 |
| Wakita, K | 1 |
| Onishi, N | 1 |
| Ishida, T | 1 |
| Watanabe, A | 1 |
| Fujiwara, H | 1 |
| Sato, Y | 1 |
| Inaba, Y | 1 |
| Yamaura, H | 1 |
| Shimamoto, H | 1 |
| Nishiofuku, H | 1 |
| Oyama, T | 1 |
| Kanemitsu, Y | 1 |
| Sawaki, A | 1 |
| Arai, Y | 1 |
| Muro, K | 1 |
| Iwamoto, S | 1 |
| Yoshioka, K | 1 |
| Hashimoto, T | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Saze, Z | 1 |
| Takahashi, K | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, H | 1 |
| Yasutome, M | 1 |
| Hiruma, K | 1 |
| Yamashita, Y | 2 |
| Funakoshi, A | 1 |
| Yamao, K | 1 |
| Nagase, M | 1 |
| Nakachi, K | 1 |
| Horikawa, Y | 1 |
| Mizuno, N | 1 |
| Hong, DS | 1 |
| Abbruzzese, JL | 2 |
| Bogaard, K | 1 |
| Lassere, Y | 2 |
| Fukushima, M | 1 |
| Mita, A | 1 |
| Kuwata, K | 1 |
| Hoff, PM | 1 |
| Kamiya, O | 1 |
| Hoshino, A | 1 |
| Ohara, K | 1 |
| Nagata, K | 1 |
| Sugihara, T | 1 |
| Yamada, M | 1 |
| Suzuki, M | 1 |
| Kimura, K | 3 |
| Fujii, S | 1 |
| Hasegawa, K | 2 |
| Kurihara, M | 3 |
| Takahashi, M | 1 |
| Akazawa, S | 1 |
| Fukuyama, Y | 1 |
| Koizumi, W | 1 |
| Hayakawa, M | 2 |
| Sasai, T | 1 |
| Sanchiz, F | 1 |
| Milla, A | 1 |
| Pazdur, R | 1 |
| Rhodes, V | 1 |
| Ajani, JA | 1 |
| Sugarman, SM | 1 |
| Patt, YZ | 1 |
| Jones, DV | 1 |
| Markowitz, AB | 1 |
| Bready, B | 1 |
| Morise, K | 1 |
| Chin, K | 1 |
| Sugihara, M | 1 |
| Morooka, Y | 1 |
| Maeda, H | 1 |
| Hattori, T | 1 |
| Saito, H | 2 |
| Tashiro, H | 1 |
| Nomura, Y | 1 |
| Ohsaki, A | 1 |
| Daniels, M | 1 |
| Díaz-Rubio, E | 2 |
| Guillem, V | 1 |
| Montero, JM | 1 |
| García-Conde, J | 1 |
| Estapé, J | 1 |
| Martín, M | 1 |
| Herranz, C | 1 |
| Ordoñez, A | 2 |
| Galán, A | 1 |
| Ono, T | 1 |
| Komatsu, M | 1 |
| Hoshino, T | 1 |
| Ishii, T | 1 |
| Fujii, K | 1 |
| Ohshima, S | 1 |
| Mikami, K | 1 |
| Masamune, O | 1 |
| Fukuda, T | 1 |
| Suga, S | 2 |
| Iwase, H | 1 |
| Shimada, M | 1 |
| Nishio, Y | 1 |
| Ichihara, T | 1 |
| Ichihara, S | 1 |
| Kusugami, K | 1 |
| González Barón, M | 2 |
| Espinosa, E | 2 |
| García Girón, C | 2 |
| de la Gándara, I | 1 |
| Espinosa, J | 1 |
| Colmenarejo, A | 1 |
| Jalón, JI | 1 |
| Fernández, Y | 1 |
| de Castro, J | 2 |
| Kurokawa, H | 1 |
| Miura, K | 1 |
| Tokudome, S | 1 |
| Murata, T | 1 |
| Kajiyama, M | 1 |
| Abad, A | 1 |
| Navarro, M | 1 |
| Sastre, J | 1 |
| Marcuello, E | 1 |
| Aranda, E | 1 |
| Gallén, M | 1 |
| Fernandez-Martos, C | 1 |
| Martín, C | 1 |
| Zamora, P | 1 |
| García Alfonso, P | 1 |
| Garrido, P | 1 |
| Belón, J | 1 |
| Kim, YH | 1 |
| Shin, SW | 1 |
| Kim, BS | 1 |
| Park, YT | 1 |
| Kim, JG | 1 |
| Kim, JS | 1 |
| Horikoshi, N | 1 |
| Aiba, K | 1 |
| Kanamaru, R | 1 |
| Takeda, S | 1 |
| Taguchi, T | 2 |
| Niitani, H | 1 |
| Furue, H | 1 |
| Abe, T | 1 |
| Yamashita, F | 1 |
| Tanaka, M | 1 |
| Fukumori, K | 1 |
| Ando, E | 1 |
| Yano, Y | 1 |
| Kato, O | 1 |
| Yamamoto, H | 2 |
| Fukuda, H | 1 |
| Kusaba, T | 1 |
| Tanikawa, K | 1 |
| Sata, M | 1 |
| Muggia, FM | 1 |
| Wu, X | 1 |
| Spicer, D | 1 |
| Groshen, S | 1 |
| Jeffers, S | 1 |
| Leichman, CG | 1 |
| Leichman, L | 1 |
| Chan, KK | 1 |
| Mani, S | 1 |
| Kugler, JW | 1 |
| Sciortino, DF | 1 |
| Garcia, JC | 1 |
| Ansari, RH | 1 |
| Humerickhouse, R | 1 |
| Michelassi, F | 1 |
| Posner, MC | 1 |
| Shulman, KL | 1 |
| Schilsky, RL | 1 |
| List, M | 1 |
| Vokes, EE | 1 |
| Benner, S | 1 |
| Lin, JK | 1 |
| Wang, WS | 1 |
| Hsieh, RK | 1 |
| Hsu, TC | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Fan, FS | 1 |
| Yen, CC | 1 |
| Lin, TC | 1 |
| Jiang, JK | 1 |
| Yang, SH | 1 |
| Wang, HS | 1 |
| Chen, PM | 1 |
| Seto, T | 1 |
| Yoh, K | 1 |
| Asoh, H | 1 |
| Semba, H | 1 |
| Ichinose, Y | 1 |
| Adimi, P | 1 |
| Hansen, F | 1 |
| Kjaer, M | 1 |
| Aabo, K | 1 |
| Keldsen, N | 1 |
| Pfeiffer, P | 1 |
| Sandberg, E | 1 |
| Jakobsen, A | 1 |
| Ohyama, M | 1 |
| Matsumura, M | 1 |
| Katsuta, K | 1 |
| Nobori, T | 1 |
| Matsuyama, H | 1 |
| Fukami, K | 1 |
| Kiyota, R | 1 |
| Yano, H | 1 |
| Shima, T | 1 |
| Ogawa, K | 1 |
| Nagai, H | 1 |
| Horiuchi, Y | 1 |
| Kyokane, K | 1 |
| Miwa, Y | 1 |
| Aoki, Y | 1 |
| Yasue, K | 1 |
| Noro, T | 1 |
| Kamikawa, R | 1 |
| Ninomiya, E | 1 |
| Ota, K | 1 |
| Niijima, T | 1 |
| Aso, Y | 1 |
| Akaza, H | 1 |
| Kameyama, S | 1 |
| Koiso, K | 1 |
| Kawabe, K | 1 |
| Kawamura, T | 1 |
| Isurugi, K | 1 |
| Shoji, F | 1 |
| Naito, K | 1 |
| Hisazumi, H | 1 |
| Misaki, T | 1 |
| Shimada, K | 1 |
| Miyazaki, K | 1 |
| Kosaka, S | 1 |
| Miyagi, T | 1 |
| Garbuz, VM | 1 |
Clinical Trials (4)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection[NCT04369807] | 693 participants (Actual) | Observational | 2020-04-21 | Completed | |||
| A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis[NCT02912260] | Phase 2 | 125 participants (Actual) | Interventional | 2016-09-30 | Active, not recruiting | ||
| A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Oral Doses of RJ4287 in Healthy Volunteers[NCT05921006] | Phase 1 | 98 participants (Anticipated) | Interventional | 2023-06-13 | Recruiting | ||
| Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine[NCT06083636] | 500 participants (Anticipated) | Observational | 2022-07-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
1 review available for uracil and Nausea
| Article | Year |
|---|---|
Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell | 2010 |
Trials
27 trials available for uracil and Nausea
| Article | Year |
|---|---|
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross- | 2016 |
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ad | 2004 |
A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Prot | 2005 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2005 |
A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Drug Adm | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A | 2005 |
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2006 |
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asthenia; Dose-Response | 2006 |
[Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer. UFTP Study Group].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug A | 1995 |
Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; L | 1994 |
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1994 |
Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; | 1994 |
A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Meth | 1994 |
Phase II trial of UFT activity in pretreated breast cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; A | 1993 |
Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin.
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 1996 |
[Evaluation of neo-adjuvant chemotherapy for oral squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).
Topics: Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1997 |
The UFT/leucovorin/etoposide regimen for the treatment of advanced gastric cancer. Oncopaz Cooperative Group.
Topics: Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Etop | 1997 |
UFT plus cisplatin for advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrh | 1997 |
A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diarrhea; Drug Co | 1997 |
[Phase I study of orally administered UFT plus l-leucovorin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor | 1996 |
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leuc | 1998 |
A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cel | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2002 |
Other Studies
22 other studies available for uracil and Nausea
| Article | Year |
|---|---|
Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antimetabolites, Antineoplastic; Antineo | 2014 |
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female; | 2016 |
[Neoadjuvant chemotherapy with nedaplatin and UFT for oral squamous cell carcinomas].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2003 |
URACIL MUSTARY THERAPY IN METASTATIC WILMS'S TUMOR.
Topics: Anemia; Child; Drug Therapy; Leukopenia; Nausea; Neoplasm Metastasis; Nitrogen Mustard Compounds; Th | 1964 |
[Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administration | 2004 |
[Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
[Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2006 |
[A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency].
Topics: Adult; Anorexia; Antimetabolites, Antineoplastic; Bone Neoplasms; Cerebral Hemorrhage; Dihydropyrimi | 2006 |
[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Pr | 1983 |
[UFT].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combina | 1984 |
[A case of advanced gastric cancer with multiple liver metastasis successfully treated with combination chemotherapy using UFT, CDDP and etoposide].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 1996 |
Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Antidotes; Antimetabolites, Antineop | 1997 |
Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
[A comparative study of UFT enteric-coated granules with UFT capsules on the occurrence of side effects in patients with head and neck cancers--a special attention to the upper gastrointestinal tract disorders].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capsules; Diarrhea; | 1990 |
[Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 1990 |
[Report on nationwide pooled data and cohort investigation in UFT phase II study].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche | 1987 |
[Collaborative study of UFT in far-advanced renal cell carcinoma. Urological Cooperative UFT Study Group].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug A | 1988 |
[Clinical effect of UFT on prostatic cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Hum | 1985 |
[Effect of pentoxyl on the effectiveness of antibacterial agents in the treatment of pulmonary tuberculosis].
Topics: Antitubercular Agents; Blood; Body Weight; Heartburn; Humans; Nausea; Respiratory Function Tests; St | 1971 |